These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 3019236)

  • 41. Antipoliovirus activity of isothiazole derivatives: mode of action of 5,5'-diphenyl-3,3'-diisothiazole disulfide (DID).
    Garozzo A; Pinizzotto MR; Guerrera F; Tempera G; Castro A; Geremia E
    Arch Virol; 1994; 135(1-2):1-11. PubMed ID: 8198435
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Effect of D-penicillamine on poliovirus replication in HeLa cells.
    Merryman P; Jaffe IA; Ehrenfeld E
    J Virol; 1974 Apr; 13(4):881-7. PubMed ID: 4362514
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A study of the kinetics of protein and RNA synthesis induced by foot-and-mouth disease virus.
    Brown F; Martin SJ; Underwood B
    Biochim Biophys Acta; 1966 Oct; 129(1):166-77. PubMed ID: 4291133
    [No Abstract]   [Full Text] [Related]  

  • 44. Structural analysis of a series of antiviral agents complexed with human rhinovirus 14.
    Badger J; Minor I; Kremer MJ; Oliveira MA; Smith TJ; Griffith JP; Guerin DM; Krishnaswamy S; Luo M; Rossmann MG
    Proc Natl Acad Sci U S A; 1988 May; 85(10):3304-8. PubMed ID: 2835768
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Mechanical stiffening of human rhinovirus by cavity-filling antiviral drugs.
    Valbuena A; Rodríguez-Huete A; Mateu MG
    Nanoscale; 2018 Jan; 10(3):1440-1452. PubMed ID: 29302674
    [TBL] [Abstract][Full Text] [Related]  

  • 46. WIN 52035-2 inhibits both attachment and eclipse of human rhinovirus 14.
    Shepard DA; Heinz BA; Rueckert RR
    J Virol; 1993 Apr; 67(4):2245-54. PubMed ID: 8383239
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Synthesis and evaluation of peptidyl Michael acceptors that inactivate human rhinovirus 3C protease and inhibit virus replication.
    Kong JS; Venkatraman S; Furness K; Nimkar S; Shepherd TA; Wang QM; Aubé J; Hanzlik RP
    J Med Chem; 1998 Jul; 41(14):2579-87. PubMed ID: 9651162
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Thermal inactivation of oral polio vaccine: contribution of RNA and protein inactivation.
    Rombaut B; Verheyden B; Andries K; Boeyé A
    J Virol; 1994 Oct; 68(10):6454-7. PubMed ID: 8083982
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Conformational change in the floor of the human rhinovirus canyon blocks adsorption to HeLa cell receptors.
    Pevear DC; Fancher MJ; Felock PJ; Rossmann MG; Miller MS; Diana G; Treasurywala AM; McKinlay MA; Dutko FJ
    J Virol; 1989 May; 63(5):2002-7. PubMed ID: 2539499
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Chloroquine induces empty capsid formation during poliovirus eclipse.
    Kronenberger P; Vrijsen R; Boeyé A
    J Virol; 1991 Dec; 65(12):7008-11. PubMed ID: 1658391
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Synthesis and evaluation of antirhinovirus activity of 3-hydroxy and 3-methoxy 2-styrylchromones.
    Desideri N; Mastromarino P; Conti C
    Antivir Chem Chemother; 2003 Jul; 14(4):195-203. PubMed ID: 14582848
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Adenosine N1-oxide inhibits vaccinia virus replication by blocking translation of viral early mRNAs.
    Kane EM; Shuman S
    J Virol; 1995 Oct; 69(10):6352-8. PubMed ID: 7666536
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A new antirhinovirus compound, ICI 73602: structure, properties, and spectrum of activity.
    Swallow DL; Bucknall RA; Stanier WE; Hutchinson A; Gaskin H
    Ann N Y Acad Sci; 1977 Mar; 284(1):305-9. PubMed ID: 212977
    [No Abstract]   [Full Text] [Related]  

  • 54. RNA and protein synthesis in rhinovirus infected HeLa cells.
    Thomas DC; Conant RM; Hamparian VV; Cramblett HG
    Proc Soc Exp Biol Med; 1972 Apr; 139(4):1441-4. PubMed ID: 4336833
    [No Abstract]   [Full Text] [Related]  

  • 55. 3,4-Dihydro-2-phenyl-2H-pyrano[2,3-b]pyridines with potent antirhinovirus activity.
    Bargar TM; Dulworth JK; Kenny MT; Massad R; Daniel JK; Wilson T; Sargent RN
    J Med Chem; 1986 Sep; 29(9):1590-5. PubMed ID: 3018241
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Molecular basis of drug resistance to new antirhinovirus agents.
    Ishitsuka H; Ninomiya Y; Suhara Y
    J Antimicrob Chemother; 1986 Oct; 18 Suppl B():11-8. PubMed ID: 3025150
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Stabilization of human rhinovirus serotype 2 against pH-induced conformational change by antiviral compounds.
    Gruenberger M; Pevear D; Diana GD; Kuechler E; Blaas D
    J Gen Virol; 1991 Feb; 72 ( Pt 2)():431-3. PubMed ID: 1847178
    [TBL] [Abstract][Full Text] [Related]  

  • 58. SCH 38057: a picornavirus capsid-binding molecule with antiviral activity after the initial stage of viral uncoating.
    Rozhon E; Cox S; Buontempo P; O'Connell J; Slater W; De Martino J; Schwartz J; Miller G; Arnold E; Zhang A
    Antiviral Res; 1993 May; 21(1):15-35. PubMed ID: 8391247
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Inhibitory effects of 3-imino-5-phenyl-3H-1,2-dithiole on poliovirus type 1 replication in vitro.
    Garozzo A; Pinizzotto MR; Furneri PM; Baratta D; Guerrera F; Castro A; Tornetta B; Geremia E
    Antiviral Res; 1990; 14(4-5):267-77. PubMed ID: 1965112
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Synthesis and antiviral activity of certain thiazole C-nucleosides.
    Srivastava PC; Pickering MV; Allen LB; Streeter DG; Campbell MT; Witkowski JT; Sidwell RW; Robins RK
    J Med Chem; 1977 Feb; 20(2):256-62. PubMed ID: 189032
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.